Siegfried News

1. Siegfried Delivers Profitable Growth And Confirms Outlook 9/24/2026
2. Siegfried Strengthens Manufacturing Network With New Large-Scale Drug Substance Facility In Minden 9/24/2026
3. Siegfried Successfully Places Senior Bonds Of CHF 200 Million 9/24/2026
4. Siegfried Included In Dow Jones Best-In-Class Europe Index 9/24/2026
5. Siegfried DINAMIQS Receives Swissmedic License For Viral Vector Manufacturing 9/24/2026
6. Siegfried Obtains Antitrust Clearance For Acquisition Of Three Drug Substances Sites In The US And Australia 9/24/2026
7. Siegfried Shareholders Approve All Proposals At Annual General Meeting 2026 9/24/2026
8. Siegfried Delivers Strong Profitability And Continued Growth 9/24/2026
9. Siegfried To Acquire High-Quality Small Molecules Drug Substance Capacity In The US 1/27/2026

   Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, has signed binding agreements with an affiliate of SK Capital Partners to acquire the drug substance business of the Noramco Group and Extractas Bioscience.